Why consumers pay a “trust premium” for branded generics—and what it signals for the next phase of pharma competition
In healthcare, the price you pay is rarely just a number. It’s a vote—quietly cast—about risk, reliability, and what you believe will …

AI is already “reading” your drug—whether you want it to or not.
In pharma, we’ve spent years building competitive moats around data: clinical packages, manufacturing know-how, payer narratives, and—most importantly—patent strategy. But there’s a new…

Most pharma teams don’t lose because they lack talent. They lose because they’re flying blind.
In the patent race, “knowing” isn’t the same as “seeing.” And the gap between those two states—what I’d call the intelligence gap—quietly determines who gets…

Most teams don’t lose to competitors because they’re less talented. They lose because they’re late.
In pharma, “late” can mean months—sometimes years—before a product’s protection actually expires. And when that window closes, the market doesn’t wait. …

The patent cliff isn’t a cliff anymore—it’s a battlefield.
For years, the story around “patent expiration” has been told as a simple timeline: the brand exclusivity ends, generics arrive, and the market resets. But the last few years have made that n…

AI is becoming the new “KOL” in pharma—and most teams aren’t tracking it.
For years, drugmakers have built their influence maps around familiar signals: key opinion leaders, conference circuits, advisory boards, and the slow grind of peer-reviewed evid…

Most pharma teams are looking at patent expiry the wrong way.
They’re treating out-licensing like a last-minute scramble—something you do when the patent clock is already ticking down. But the real value isn’t captured at the finish line. It’s captur…

Drug patent expiry isn’t a single date—it’s a moving target across jurisdictions. Here’s how to forecast it like a portfolio manager.
If you manage a pharma portfolio, you already know the uncomfortable truth: “patent expiry” is rarely one clean event….